Dr. Timothy N. Showalter: Pioneering AI and Oncology at Viz.ai

Health & Science

The Steward

30 Apr 2026 · 3 min read

Dr. Timothy N. Showalter leverages AI to revolutionize oncology care at Viz.ai, enhancing patient outcomes and driving innovation in drug discovery, showcasing the power of tech in modern medicine.

In an era where artificial intelligence (AI) is transforming healthcare, few individuals have had a more profound impact than Dr. Timothy N. Showalter. As the Chief Medical Officer at Viz.ai, a leading AI-powered care coordination platform, Dr. Showalter is at the forefront of integrating advanced technology into clinical practice. His work not only enhances patient outcomes but also drives innovation in drug discovery and biotech research.

A Multifaceted Career

Dr. Showalter's journey is a testament to his versatility and dedication to advancing healthcare through technology. With over 15 years of experience, he has bridged the gap between academic medicine, health technology, and medtech entrepreneurship. Currently, he serves as a practicing radiation oncologist at the University of Virginia, where he continues to treat patients while pushing the boundaries of medical research.

Leading Clinical Strategy at Viz.ai

At Viz.ai, Dr. Showalter leads the clinical strategy and evidence generation for the company's AI-powered care coordination platform. This role involves developing and implementing innovative solutions that improve patient care and streamline healthcare processes. The platform leverages AI to identify critical conditions early, ensuring timely interventions and better outcomes for patients.

A Track Record of Innovation

Dr. Showalter's career is marked by significant achievements in clinical research and technology development. He has held senior leadership roles at several pioneering companies, including Artera, where he served as Chief Medical Officer, and Flatiron Health, where he was the Medical Director. His expertise spans a wide range of areas, including clinical trial strategy, regulatory pathways, real-world evidence, and precision oncology.

One of his most notable accomplishments is founding Advaray, a medical device company that he led from its inception through FDA de novo clearance and a successful acquisition. This venture underscores his ability to translate innovative ideas into practical solutions that benefit patients and healthcare providers alike.

Contributions to Oncology Innovation

Dr. Showalter's contributions to oncology innovation are widely recognized. He has authored nearly 200 peer-reviewed publications, making him a respected authority in the field. His work focuses on advancing precision oncology, which involves tailoring cancer treatments to individual patients based on their genetic profiles and other factors. This approach not only improves treatment efficacy but also reduces side effects and enhances the quality of life for cancer patients.

The Future of AI in Healthcare

As AI continues to evolve, Dr. Showalter is committed to exploring its potential applications in healthcare. He believes that AI can revolutionize drug discovery by accelerating the development of new treatments and improving patient outcomes. By integrating real-world data and advanced analytics, AI has the power to identify new therapeutic targets and optimize clinical trials.

However, he also acknowledges the challenges and ethical considerations associated with AI in healthcare. Ensuring data privacy, maintaining transparency, and addressing biases are critical issues that must be addressed to build trust among patients and healthcare providers.

A Vision for Change

Dr. Showalter's vision is to create a future where technology and human expertise work together seamlessly to provide the best possible care. By leading clinical strategy at Viz.ai and continuing his research in oncology, he is paving the way for a more efficient, effective, and patient-centered healthcare system.